Cartesian Therapeutics, INC

Cartesian Therapeutics announced strong Q2 2026 financial results, highlighting progress in its Descartes-08 clinical trials and a strategic partnership extending cash runway into 2028.

Cartesian Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and the ratification of its independent auditor.

Cartesian Therapeutics has entered a strategic licensing agreement with WestGene Biopharma to advance in vivo CAR-T therapies for autoimmune diseases, with a clinical trial planned for 2H 2026.

Cartesian Therapeutics has secured up to $150 million in non-dilutive financing from K2 HealthVentures, extending its cash runway into 2028 and supporting advancement of its cell therapy programs.

Cartesian Therapeutics announced first quarter 2026 financial results, highlighting progress in its Descartes-08 clinical trials for autoimmune diseases and a cash runway extending into mid-2027.

Cartesian Therapeutics highlights recent progress and outlines its 2026 strategic priorities for its mRNA cell therapy pipeline, including ongoing Phase 3 MG trial and new myositis and pediatric trials.

Cartesian Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing progress in its autoimmune disease cell therapy development, securing new debt financing, and continued operational losses.

Cartesian Therapeutics reported a wider net loss for Q1 2026, primarily driven by an increase in the fair value of its contingent value right liability, alongside increased R&D expenses.

Cartesian Therapeutics reported an increased net loss for the third quarter of 2025, driven by higher research and development expenses, despite a reduced net loss for the nine-month period due to fair value adjustments.

Cartesian Therapeutics reported a net income of $15.9 million for Q2 2025, driven by fair value adjustments, despite a significant drop in collaboration revenue.

Cartesian Therapeutics announces its Q1 2025 financial results, highlighting a decrease in net loss compared to the previous year and the completion of a contingent value right (CVR) distribution.

Cartesian Therapeutics' Q3 2024 report reveals a net loss of $24.2 million, impacted by a substantial increase in the contingent value right liability, despite a rise in collaboration revenue.

Cartesian Therapeutics' 2024 10-K filing details the company's focus on mRNA cell therapy for autoimmune diseases, highlighting clinical trial results and future plans.

Cartesian Therapeutics details its registered securities, including common stock and contingent value rights, along with its capital structure, in its latest 10-K filing.

Elizabeth Hoge, a director at Cartesian Therapeutics, Inc., reported a conversion of Series A Preferred Stock into common stock and related beneficial ownership changes.

Director Murat Kalayoglu reported a conversion of preferred stock to common stock and a disposition of common stock in Cartesian Therapeutics, Inc. on April 2, 2026.

Michael Singer, a Director at Cartesian Therapeutics, Inc., reported gifting 6,555 shares of common stock on March 13, 2026.

Cartesian Therapeutics' President and CEO, Carsten Brunn, sold 23,766 shares of common stock to cover tax obligations and broker fees.

Cartesian Therapeutics' Chief Medical Officer, Milos Miljkovic, sold 3,573 shares of common stock to cover tax obligations and broker fees.

Cartesian Therapeutics CFO Blaine Davis sold 10,591 shares of common stock to cover tax obligations and broker fees related to restricted stock unit vesting.

Cartesian Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 12, 2026, to elect directors, approve executive compensation, and ratify auditor appointments.

Cartesian Therapeutics, Inc. has filed a definitive proxy statement with the SEC, related to an upcoming shareholder meeting.

Cartesian Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 13, 2025, to vote on the election of directors, executive compensation, and the ratification of the company's independent auditor.

Cartesian Therapeutics is holding a special meeting on September 20, 2024, to seek stockholder approval for the conversion of its Series B Preferred Stock into common stock.

Cartesian Therapeutics is asking stockholders to approve an amended and restated 2016 Incentive Award Plan to increase the number of shares available for equity-based compensation.

Cartesian Therapeutics, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Cartesian Therapeutics is registering for the resale of up to 6.5 million shares of its common stock by selling stockholders after a recent merger and private placement.

Cartesian Therapeutics files an amendment to its S-1 registration statement to allow selling stockholders to resell up to 6.5 million shares of common stock.

Cartesian Therapeutics has filed a registration statement for the resale of up to 6.5 million shares of its common stock by selling stockholders.

Cartesian Therapeutics, Inc. reports a director's resignation and a significant conversion of preferred stock to common stock by a major stakeholder.

Timothy A. Springer, a director of Cartesian Therapeutics, Inc., has substantially increased his beneficial ownership in the company to 36.9% through recent open market purchases and equity grants.

Barclays PLC has filed a Schedule 13G, reporting beneficial ownership of 5.99% of Cartesian Therapeutics Inc. common stock as of June 30, 2026.

JPMorgan Chase & Co. has reported a beneficial ownership of 4.8% in Cartesian Therapeutics, Inc., holding 1,486,252 shares.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 3.0% of Cartesian Therapeutics' common stock as of March 31, 2026.

Investment firm Squarepoint and its affiliates have reported a passive 8.3% beneficial ownership stake in Cartesian Therapeutics, Inc. common stock.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have reported a beneficial ownership of 5.3% in Cartesian Therapeutics Inc. as of December 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting an 8.3% beneficial ownership stake in Cartesian Therapeutics Inc.'s common stock.